T-cell-directed treatment strategies for Type 1 diabetes and the confounding role of inflammation

Immunotherapy

Volumn 2, Issue 4, 2010, Pages 431-436

  Koulmanda, Maria ^a   Strom, Terry B ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTITRYPSIN; CALCINEURIN INHIBITOR; CD3 ANTIBODY; CORTICOSTEROID; FC RECEPTOR; IMMUNOSUPPRESSIVE AGENT; INSULIN; INTERLEUKIN 15 RECEPTOR ALPHA; INTERLEUKIN 2; RAPAMYCIN; TRANSCRIPTION FACTOR FOXP3;

APOPTOSIS; AUTOIMMUNITY; B LYMPHOCYTE; CELL DESTRUCTION; CELL DIFFERENTIATION; CELL PROTECTION; CELLULAR IMMUNITY; CYTOTOXICITY; DIABETOGENESIS; DISEASE ACTIVITY; DRUG EFFICACY; DRUG TARGETING; DRUG TOLERANCE; EDITORIAL; EFFECTOR CELL; GENE MUTATION; GENETIC SUSCEPTIBILITY; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; INSULIN TREATMENT; ISOLATION AND PURIFICATION; LONG TERM CARE; MORBIDITY; PANCREAS ISLET BETA CELL; PANCREAS TRANSPLANTATION; PRIORITY JOURNAL; PROTEIN TARGETING; REMISSION; SHORT COURSE THERAPY; T LYMPHOCYTE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ALPHA 1-ANTITRYPSIN; ANIMALS; DIABETES MELLITUS, TYPE 1; HUMANS; IMMUNOTHERAPY; INFLAMMATION; MICE; SERINE PROTEINASE INHIBITORS; T-LYMPHOCYTES;

EID: 77955000879     PISSN: 1750743X     EISSN: None     Source Type: Journal    
DOI: 10.2217/imt.10.40     Document Type: Editorial

References (39)

1. Rossini AA, Mordes JP, Like AA: Immunology of insulin-dependent diabetes mellitus. Annu. Rev. Immunol. 3, 289-320 (1985).
2. Ballinger WF, Lacy PE: Transplantation of intact pancreatic islets in rats. Surgery 72, 175-186 (1972).
3. Lacy PE, Kostianovsky M: Method for the isolation of intact islets of Langerhans from the rat pancreas. Diabetes 16, 35-39 (1967).
4. Ricordi C, Strom TB: Clinical islet transplantation: advances and immunological challenges. Nat. Rev. Immunol. 4, 259-268 (2004).
5. Shapiro AM, Lakey JR, Ryan EA et al.: Islet transplantation in seven patients with Type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N. Engl. J. Med. 343, 230-238 (2000).
6. Shapiro AM, Ricordi C, Hering BJ et al.: International trial of the Edmonton protocol for islet transplantation. N. Engl. J. Med. 355, 1318-1330 (2006).
7. Herold KC, Hagopian W, Auger JA et al.: Anti-CD3 monoclonal antibody in new-onset Type 1 diabetes mellitus. N. Engl. J. Med. 346, 1692-1698 (2002).
8. Shoda LK, Young DL, Ramanujan S et al.: A comprehensive review of interventions in the NOD mouse and implications for translation. Immunity 23, 115-126 (2005).
9. Belghith M, Bluestone JA, Barriot S et al.: TGF-b-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat. Med. 9, 1202-1208 (2003).
10. Koulmanda M, Budo E, Bonner-Weir S et al.: Modification of adverse inflammation is required to cure new-onset Type 1 diabetic hosts. Proc. Natl Acad. Sci. USA 104, 13074-13079 (2007).
11. Ogawa N, List JF, Habener JF, Maki T: Cure of overt diabetes in NOD mice by transient treatment with anti-lymphocyte serum and exendin-4. Diabetes 53, 1700-1705 (2004).
12. + CD25+ CD62L+ regulatory T cells restore normoglycemia in diabetic NOD mice. J. Exp. Med. 204, 191-201 (2007).
13. Bresson D, Togher L, Rodrigo E et al.: Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs. J. Clin. Invest. 116, 1371-1381 (2006).
14. Bettelli E, Carrier Y, Gao W et al.: Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441, 235-238 (2006).
15. Tato CM, OShea JJ: Immunology: what does it mean to be just 17? Nature 441, 166-168 (2006).
16. Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B: TGFb in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17- producing T cells. Immunity 24, 179-189 (2006).
17. Barshes NR, Wyllie S, Goss JA: Inflammation-mediated dysfunction and apoptosis in pancreatic islet transplantation: implications for intrahepatic grafts. J. Leukoc. Biol. 77, 587-597 (2005).
18. Eizirik DL, Mandrup-Poulsen T: A choice of death - the signal-transduction of immune-mediated b-cell apoptosis. Diabetologia 44, 2115-2133 (2001).
19. Hotamisligil GS: Inflammation and metabolic disorders. Nature 444, 860-867 (2006).
20. Sandler S, Andersson A, Hellerstrom C: Inhibitory effects of interleukin 1 on insulin secretion, insulin biosynthesis, and oxidative metabolism of isolated rat pancreatic islets. Endocrinology 121, 1424-1431 (1987).
21. Zheng XX, Sanchez-Fueyo A, Sho M et al.: Favorably tipping the balance between cytopathic and regulatory T cells to create transplantation tolerance. Immunity 19, 503-514 (2003).
22. Fontenot JD, Rasmussen JP, Gavin MA, Rudensky AY: A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat. Immunol. 6, 1142-1151 (2005).
23. Zheng XX, Maslinski W, Ferrari-Lacraz S, Strom TB: Cytokines in the treatment and prevention of autoimmune responses - a role of IL-15. Adv. Exp. Med. Biol. 520, 87-95 (2003).
24. Ferrari-Lacraz S, Zheng XX, Kim YS et al.: An antagonist IL-15/Fc protein prevents costimulation blockade-resistant rejection. J. Immunol. 167, 3478-3485 (2001).
25. Waldmann TA, Dubois S, Tagaya Y: Contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for immunotherapy. Immunity 14, 105-110 (2001).
26. Li Y, Li XC, Zheng XX et al.: Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. Nat. Med. 5, 1298-1302 (1999).
27. Zheng XX, Steele AW, Hancock WW et al.: IL-2 receptor-targeted cytolytic IL-2/Fc fusion protein treatment blocks diabetogenic autoimmunity in nonobese diabetic mice. J. Immunol. 163, 4041-4048 (1999).
28. Breit SN, Wakefield D, Robinson JP et al.: The role of a 1-antitrypsin deficiency in the pathogenesis of immune disorders. Clin. Immunol. Immunopathol. 35, 363-380 (1985).
29. Churg A, Dai J, Zay K et al.: a-1-antitrypsin and a broad spectrum metalloprotease inhibitor, RS113456, have similar acute anti-inflammatory effects. Lab. Invest. 81, 1119-1131 (2001).
30. Jie Z, Cai Y, Yang W et al.: Protective effects of a 1-antitrypsin on acute lung injury in rabbits induced by endotoxin. Chin. Med. J. (Engl.) 116, 1678-1682 (2003).
31. Lewis EC, Shapiro L, Bowers OJ, Dinarello CA: a1-antitrypsin monotherapy prolongs islet allograft survival in mice. Proc. Natl Acad. Sci. USA 102, 12153-12158 (2005).
32. Petrache I, Fijalkowska I, Zhen L et al.: A novel antiapoptotic role for a1-antitrypsin in the prevention of pulmonary emphysema. Am. J. Respir. Crit. Care Med. 173, 1222-1228 (2006).
33. Abbas AK, Corson JM, Carpenter CB et al.: Immunologic enhancement of rat renal allografts. III. Immunopathologic lesions and rejection in long-surviving passively enhanced grafts. Am. J. Pathol. 79, 255-270 (1975).
34. Brantly M: a1-antitrypsin: not just an antiprotease: extending the half-life of a natural anti-inflammatory molecule by conjugation with polyethylene glycol. Am. J. Respir. Cell Mol. Biol. 27, 652-654 (2002).
35. Koulmanda M, Bhasin M, Hoffman L et al.: Curative and b cell regenerative effects of a1-antitrypsin treatment in autoimmune diabetic NOD mice. Proc. Natl Acad. Sci. USA 105, 16242-16247 (2008).
36. Bruning JC, Winnay J, Bonner-Weir S et al.: Development of a novel polygenic model of NIDDM in mice heterozygous for IR and IRS-1 null alleles. Cell 88, 561-572 (1997).
37. Chaparro RJ, Konigshofer Y, Beilhack GF et al.: Nonobese diabetic mice express aspects of both Type 1 and Type 2 diabetes. Proc. Natl Acad. Sci. USA 103, 12475-12480 (2006).
38. Shoelson SE, Lee J, Goldfine AB: Inflammation and insulin resistance. J. Clin. Invest. 116, 1793 - 1801 (2006).
39. Hotamisligil GS, Shargill NS, Spiegelman BM: Adipose expression of tumor necrosis factor-α: direct role in obesity-linked insulin resistance. Science 259, 87-91 (1993)